Skip to main content

Apollomics Inc.

corporate_fare Company Profile

Apollomics Inc.

APLM·NASDAQ·Life Sciences·CIK 0001944885

Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer treatments. The company's approach involves harnessing the immune system and targeting specific molecular pathways to inhibit cancer growth. Its product portfolio includes Vebreltinib (APL-101), an oral, highly selective c-Met inhibitor currently in Phase 2 clinical trials for non-small cell lung cancer and other solid tumors with MET dysregulation. APL-102, an oral small molecule multiple tyrosine kinase inhibitor, is in a Phase 1 clinical trial to inhibit various kinases activated in cancer cells. Additionally, APL-122 is a tumor inhibitor candidate targeting ErbB1/2/4 signaling pathways, which is in Phase 1 dose escalation clinical trials for treating brain cancers. The company also has immuno-oncology product candidates, including APL-501, APL-502, and APL-801. Apollomics, Inc. was founded in 2015 and is based in Foster City, California.

Apollomics Inc. (NASDAQ:APLM) is a publicly traded company in the Life Sciences sector. Wiseek monitors APLM SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Apollomics Regains Nasdaq Compliance, Delisting Threat Lifted
  • Apollomics Terminates Key Partnership Due to Material Breach, Initiates Dispute Resolution
  • Apollomics Faces Nasdaq Delisting Risk, Terminates $3.8M Licensing Deal
  • Apollomics Reports FY25 Financials, Details Turnaround Efforts & Clinical Progress for Vebreltinib
  • Apollomics Discloses Going Concern Doubt Amidst Low Cash, Clinical Setbacks, and Dilutive CEO Loan

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$8.5M
Net Income
-$10.94M
Diluted EPS
-$7.57
Op. Cash Flow
-$10.37M
Cash & Equivalents
$3.28M
Debt / Equity
0.00×
Net Margin
-128.7%
Source: 20-F · filed 2026-04-24 · accession 0001193125-26-177357

Insider Transactions

APLM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with A →
$18.86
52-week range · as of 2026-06-24 $3.66 – $42.12
Market cap
$39.99M
Volume
13.1K (0.5× avg)
3-mo avg 27.2K
Live data · 2026-07-26 20:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed APLM - Latest Insights

APLM
Jul 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Apollomics Regains Nasdaq Compliance, Delisting Threat Lifted
Price at Filing: $18.95
Real-time Price: $18.86 info
Change: -$0.090 (-0.47%) info
Market Cap: $39.99M info
Sentiment: Positive
View Wiseek Article
APLM
Jun 24, 2026, 6:28 PM EDT
Source: Reuters
Importance Score:
8
Apollomics Terminates Key Partnership Due to Material Breach, Initiates Dispute Resolution
Price at Filing: $20.50
Real-time Price: $18.86 info
Change: -$1.64 (-8%) info
Market Cap: $39.99M info
Sentiment: Negative
View Wiseek Article
APLM
Jun 24, 2026, 5:11 PM EDT
Filing Type: 6-K
Importance Score:
8
Apollomics Faces Nasdaq Delisting Risk, Terminates $3.8M Licensing Deal
Price at Filing: $20.50
Real-time Price: $18.86 info
Change: -$1.64 (-8%) info
Market Cap: $39.99M info
Sentiment: Negative
View Wiseek Article
APLM
Apr 27, 2026, 8:20 AM EDT
Filing Type: 6-K
Importance Score:
7
Apollomics Reports FY25 Financials, Details Turnaround Efforts & Clinical Progress for Vebreltinib
Price at Filing: $13.28
Real-time Price: $18.86 info
Change: +$5.58 (+42%) info
Market Cap: $39.99M info
Sentiment: Neutral
View Wiseek Article
APLM
Apr 24, 2026, 4:24 PM EDT
Filing Type: 20-F
Importance Score:
9
Apollomics Discloses Going Concern Doubt Amidst Low Cash, Clinical Setbacks, and Dilutive CEO Loan
Price at Filing: $13.28
Real-time Price: $18.86 info
Change: +$5.58 (+42%) info
Market Cap: $39.99M info
Sentiment: Negative
View Wiseek Article
APLM
Apr 08, 2026, 7:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
COO/Director Yi-Kuei Chen Discloses 5.3% Beneficial Ownership, Valued at Over $1.7 Million
Price at Filing: $15.40
Real-time Price: $18.86 info
Change: +$3.46 (+22%) info
Market Cap: $39.99M info
Sentiment: Positive
View Wiseek Article
APLM
Apr 01, 2026, 4:52 PM EDT
Filing Type: 6-K
Importance Score:
9
CEO Provides $2.0M Interest-Free Convertible Loan to Fund Clinical Operations
Price at Filing: $14.72
Real-time Price: $18.86 info
Change: +$4.14 (+28%) info
Market Cap: $39.99M info
Sentiment: Positive
View Wiseek Article
APLM
Mar 09, 2026, 5:16 PM EDT
Filing Type: F-3
Importance Score:
8
Selling Securityholders Register $5.6M in Class A Shares for Resale, Creating Market Overhang
Price at Filing: $20.01
Real-time Price: $18.86 info
Change: -$1.15 (-6%) info
Market Cap: $39.99M info
Sentiment: Negative
View Wiseek Article